Sionna Therapeutics (SION) – Investment Analysts’ Recent Ratings Updates

Sionna Therapeutics (NASDAQ: SION) has recently received a number of price target changes and ratings updates:

• 5/26/2026 – Sionna Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $63.00 price target on the stock.
• 5/20/2026 – Sionna Therapeutics was downgraded by Freedom Capital from “strong-buy” to “hold”.
• 5/18/2026 – Sionna Therapeutics had its price target raised by Stifel Nicolaus from $44.00 to $55.00. They now have a “buy” rating on the stock.
• 5/16/2026 – Sionna Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 5/13/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.
• 5/8/2026 – Sionna Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 5/5/2026 – Sionna Therapeutics is now covered by Wedbush. They set an “outperform” rating and a $53.00 price target on the stock.
• 5/4/2026 – Sionna Therapeutics was upgraded by Wedbush to “strong-buy”.
• 4/28/2026 – Sionna Therapeutics had its price target raised by JonesTrading from $52.00 to $63.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Sionna Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $58.00 price target on the stock.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total value of $10,528,924.32. Following the sale, the director directly owned 3,247,025 shares of the company’s stock, valued at $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 235,863 shares of the company’s stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32. Following the completion of the sale, the director directly owned 3,247,025 shares in the company, valued at $144,947,196. This represents a 6.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,717,962 shares of company stock worth $77,571,889. Corporate insiders own 5.10% of the company’s stock.

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.